Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To demonstrate that sarilumab (SAR153191/REGN88) on top of methotrexate (MTX) was superior
in efficacy to placebo for the relief of signs and symptoms of rheumatoid arthritis (RA), in
participants with active RA who had failed up to 2 tumor necrosis factor-alpha (TNF-α)
antagonists.
Secondary Objectives:
- To assess the safety of sarilumab;
- To document the pharmacokinetic profile of sarilumab.